Search Follow us

Oxford BioMedica (OXB)

Business description

Oxford BioMedica’s (OXB) LentiVector technology underpins the company’s strategy. OXB generates significant revenue from partners that utilise its technology, notably Novartis, Bioverativ, Orchard Therapeutics and Immune Design. OXB is in partnering discussions about internally developed assets.

Stock data

Market cap.£437.8m
Last close662.10p
High / Low (52 weeks)1050.0p / 526.0p
Stock market listingLN
Forecast net debt (£m)3.9
Forecast gearing ratio (%)12
TeamHealthcare
SectorPharmaceuticals & healthcare

Price performance

%1m3m12m
Actual5.00.312.2
Relative *1.6(2.4)13.9

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acacia Pharma Acarix
Acerus Pharmaceuticals Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Actinogen Medical Active Biotech
Acucela Addex Therapeutics
Adherium ADL Bionatur Solutions
Adocia Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
AFT Pharmaceuticals Agennix
Akari Therapeutics Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Allium Medical Solutions
Alnylam Pharmaceuticals Amarantus BioScience
Amarin Amplifon
AmpliPhi Biosciences Angle
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Antibe Therapeutics
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma ASIT biotech
ASLAN Pharmaceuticals Astex Pharmaceuticals
Athersys Atossa Genetics
Auris Medical Holding Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Avivagen
Balda Basilea Pharmaceutica
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLargo
BioLight Life Sciences BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma BioPorto Diagnostics
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
Bone Therapeutics Bonesupport
BrainStorm Cell Therapeutics Brighter
BTG C4X Discovery Holdings
Caladrius Biosciences Can-Fite BioPharma
CannTrust Holdings Cantargia
Capstone Therapeutics Carmat
CASI Pharmaceuticals Cell Therapy
Celldex Therapeutics Cellectis
Cellular Biomedicine Group Celyad
Cerulean Pharma Circadian Technologies
Circassia Pharmaceuticals Clal Biotechnology Industries
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
CO.DON CollPlant Holdings
Consort Medical Corium International
Crescendo Crossject
CSL Curetis NV
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Deinove Delcath Systems
Deltex Medical Derma Sciences
Destiny Pharma DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Elbit Medical Technologies Ellex Medical Lasers
Emergent BioSolutions Endocyte
Epigenomics Ergomed
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis Expedeon
EyeGate Pharmaceuticals Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Heat Biologics Inc. Heidelberg Pharma
Herantis Pharma Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings Immunovia
ImmuPharma Immutep
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
InflaRx InMed Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico Japan Tobacco
KaloBios Pharmaceuticals Kane Biotech
Karolinska Development Kazia Therapeutics
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medicure
Medigene MedinCell
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MGC Pharmaceuticals
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt NPS Pharmaceuticals
Nuevolution Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncology Venture
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Orgenesis
Oryzon Genomics OSE Immunotherapeutics
Ossur OvaScience
OWL Oxford Immunotec
Pacific Edge Paion
Paladin Labs Patheon
PBKM PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Genomics
Quantum Pharmaceuticals Race Oncology
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shield Therapeutics
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
T‐cell cancer therapies Targovax
TearLab Corp Tekmira
Telix Pharmaceuticals TESARO
Theraclion Therapix Biosciences
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics True Leaf
TruScreen TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

Oxford BioMedica's shares shares rise after unveiling US$100mln agreement with ...

Thu, 15 Feb 2018 10:11:25 GMT

Oxford Biomedica (LSE:OXB) Share Price

Fri, 20 Dec 2013 02:29:24 GMT

Investors Chronicle: Redrow, Oxford BioMedica, Halfords

Fri, 08 Sep 2017 15:08:45 GMT

Investors Chronicle: Bellway, M&C Saatchi, Oxford Biomedica

Fri, 24 Mar 2017 18:00:00 GMT

Oxford BioMedica's borrowings cloud growth opportunities

Fri, 16 Mar 2018 11:35:39 GMT

Y/E Dec Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2016A 27.8 (7.6) (20.0) (29.35) N/A N/A
2017A 37.6 (1.3) (11.5) (14.14) N/A N/A
2018E 74.3 15.5 3.8 4.80 137.9 24.7
2019E 85.1 18.3 4.6 5.65 117.2 27.3

Last updated on 17/12/2018

Investment summary

Oxford BioMedica (OXB) is a global leader in lentiviral development and manufacturing. Maiden interim profits reported this year are evidence of strong operational momentum and ongoing validation of its business model. On the back of a £19.3m net raise in March, OXB is expanding its manufacturing capabilities to match increasing demand and continued growth of its platform (partnership) revenues. In the near term, revenue will continue to be driven by the Novartis partnership as Kymriah's commercial roll out continues (royalties and manufacturing fees). OXB has several established development and manufacturing partnerships with Bioverativ, Sanofi & Orchard Therapeutics and continues to look to spin-out/out-license its internally developed, preclinical assets. Recently, partner Axovant announced that the development of AXO-Lenti-PD (in-licensed from OXB) was proceeding according to plan, with the first data from the ongoing SUNRISE-PD Phase II trial expected in Q119. As of 30 June, OXB had gross cash of £44.0m.

Last updated on 01/02/2019

Industry outlook

Cell- and gene-therapy is the focus of much industry attention as it can dramatically alter the outcomes of many diseases. The proprietary lentivector platform has demonstrated promise in many indications.

Last updated on 01/02/2019

Key management

Dr. Lorenzo Tallarigo, Chairman
John Dawson, CEO
Stuart Paynter, Chief Financial Officer

Company address

Medawar Centre
Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA
United Kingdom
+44 (0) 1865 783 000
View website